Monitoring for teratogenic signals: Pregnancy registries and surveillance methods

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 157, Issue 3, 2011, Pages 209-214

  Howard, Tammie B ^a   Tassinari, Melissa S ^a   Feibus, Karen B ^b   Mathis, Lisa L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Fetal risk and medication; Medication and pregnancy; Pregnancy exposure registry; Pregnancy surveillance programs; Teratogenic signal detection

Indexed keywords

ADVERSE OUTCOME; ARTICLE; BIRTH DEFECT; CASE CONTROL STUDY; COHORT ANALYSIS; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENETIC RISK; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; MONITORING; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; TERATOGENESIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; DRUG LABELING; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS; REGISTRIES; RISK ASSESSMENT; TERATOGENS;

EID: 79960566091     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30304     Document Type: Article

References (30)

1. Amgen prescribing information. 2011., accessed 1 March 2011.
2. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. 2009. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. Am J Med Genet Part A 149A: 1241-1248.
3. CellCept (mycophenolate mofetil). 2011. Roche Palo, label 10/8/2009, accessed 1 March 2011.
4. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354: 579-587.
5. Chang S, Ball R, Braun MM. 2008. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. Vaccine 26: 2428-2432.
6. Depakote (divalproex sodium). 2011. Abbott, label 4/323/09, accessed 1 March 2011.
7. Euser AM, Zoccali C, Jager KJ, Dekker FW. 2009. Cohort studies: Prospective versus retrospective. Nephron Clin Pract 113: c214-c217.
8. FDA. 2002. Guidance for Industry, Establishing Pregnancy Registries, August 2002.
9. FDA. 2005. Reviewer Guidance, Evaluating the Risk of Drug Exposure in Human Pregnancies April 2005.
10. FDAAA. 2007. US Food and Drug Administration Amendments Act (FDAAA) of 2007, Pub. L. No. 75-711, 52 Stat. 1040 (1938) as amended.
11. Herbst AL, Ulfelder H, Poskanzer DC. 1971. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284: 878-881.
12. Holmes LB. 2011. Human teratogens: Update 2010. Birth Defects Res A Clin Mol Teratol 91: 1-7.
13. Irl C, Hasford J. 2000. Assessing the safety of drugs in pregnancy, the role of prospective cohort studies. Drug Safety 22: 169-177.
14. Kennedy DL, Uhl K, Kweder SL. 2004. Pregnancy exposure registries. Drug Safety 27: 215-228.
15. Kweder SL. 2008. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Birth Defects Res A Clin Mol Teratol 82: 605-609.
16. Lexapro (escitalopram oxalate). Forest Labs label 3/19/09, accessed 1 March 2011.
17. Mathis LL, Iyasu S. 2007. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: What the FDA has learned. Clin Pharmacol Ther 82: 133-134.
18. McKeigue PM, Lamm SH, Linn S, Kutcher JS. 1994. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 50: 27-37.
19. Merck. 2011., accessed 1 March 2011.
20. NBDPS. 2011. National Birth Defects Prevention Study, accessed May 2011.
21. OWH. 2011. Office of Women's Health, US Food and Drug Administration, accessed 1 March 2011.
22. PLR. 2006. Physician Labeling Rule. Federal Register Notice Vol. 71, No. 15, 1/24/06. p 3922-3997.
23. Scheuerle A, Vannappagari VX, Miller MK. 2009. Measurements of birth defect prevalence: Which is most useful as a comparator group for pharmaceutical pregnancy registries? Birth Defects Res A Clin Mol Teratol 85: 611-620.
24. Schwartz EB, Santucci A, Borrero S, Akers AY, Nikolaski C, Gold MA. 2009. Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol 85: 858-863.
25. Shields KE, Wiholm B-E, Hostelley LS, Striano LF, Arena SR, Sharrar RG. 2004. Monitoring outcomes of pregnancy following drug exposure. Drug Safety 27: 353-367.
26. Smith CR, Holmes LB. 2008. Recruitment of an unexposed control group for a pregnancy registry. Birth Defects Res A Clin Mol Teratol 82: 311.
27. VAMPPS. 2011. Vaccine and Medication in Pregnancy Surveillance System., accessed 1 March, 2011.
28. Werler MM, Louik C, Mitchell AA. 2011. Case-control studies for identifying novel teratogens. Am J Med Genet Part C: 9999.
29. Wysowski DK, Swartz L. 2005. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 165: 1362-1369.
30. Wyszynski D. 2009. Pregnancy exposure registries: Academic opportunities and industry responsibility. Birth Defects Res A Clin Mol Teratol 85: 93-101.